Table 1.
Donor demographic characteristics and SARS-CoV-2 vaccination status by serology status (n = 180).
| SARS-CoV-2 Serology Status | P-value* | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antibody negativen = 90 | Antibody positiven = 90 | |||||||||||||
| Age, Median (IQR) | 34 | (9, | 54) | 46 | (9, | 71) | 0.5 | |||||||
| Age Group, n (%) | under 18 | 29 | 32.2% | 31 | 34.4% | 0.003 | ||||||||
| 18–25 | 7 | 7.8% | 0 | 0.0% | ||||||||||
| 26–45 | 22 | 24.4% | 14 | 15.6% | ||||||||||
| 46–55 | 11 | 12.2% | 9 | 10.0% | ||||||||||
| 56–65 | 12 | 13.3% | 8 | 8.9% | ||||||||||
| 66–75 | 5 | 5.6% | 14 | 15.6% | ||||||||||
| above 75 | 4 | 4.4% | 14 | 15.6% | ||||||||||
| Sex, n (%) | Female | 45 | 50.0% | 35 | 38.9% | 0.15 | ||||||||
| Male | 15 | 16.7% | 25 | 27.8% | ||||||||||
| Unknown | 30 | 33.3% | 30 | 33.3% | ||||||||||
| Vaccination Status | Unvaccinated | 73 | 81.1% | 1 | 1.1% | <0.001 | ||||||||
| 1 Dose | 9 | 10.0% | 38 | 42.2% | ||||||||||
| 2 Doses | 2 | 2.2% | 20 | 22.2% | ||||||||||
| Unknown | 6 | 6.7% | 31 | 34.4% | ||||||||||
| Vaccine dose 1 Type (brand) | AstraZeneca | 3 | 3.3% | 5 | 5.6% | <0.001 | ||||||||
| Moderna | 1 | 1.1% | 12 | 13.3% | ||||||||||
| Pfizer/BioNTech | 7 | 7.8% | 41 | 45.6% | ||||||||||
| Not Immunized | 79 | 87.8% | 32 | 35.6% | ||||||||||
| Vaccine dose 2 type (brand) | Moderna | 0 | 0.0% | 8 | 8.9% | <0.001 | ||||||||
| Pfizer/BioNTech | 2 | 2.2% | 23 | 25.6% | ||||||||||
| Not Immunized | 88 | 97.8% | 59 | 65.6% | ||||||||||
Serology status was defined based on the first Abbott Architect RBD results used for sample selection.
⁎
Mann-Whitney U test for Age and Chi-square test or Fisher's exact test for all categorical variables, unknown or not immunized groups not included in the analyses.